Browse TRPM7

Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF02816 Alpha-kinase family
PF00520 Ion transport protein
PF16519 Tetramerisation domain of TRPM
Function

Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental process that adjusts plasma membrane divalent cation fluxes according to the metabolic state of the cell. Phosphorylates annexin A1 (ANXA1).

> Gene Ontology
 
Biological Process GO:0006816 calcium ion transport
GO:0006875 cellular metal ion homeostasis
GO:0007160 cell-matrix adhesion
GO:0010960 magnesium ion homeostasis
GO:0010961 cellular magnesium ion homeostasis
GO:0016340 calcium-dependent cell-matrix adhesion
GO:0031032 actomyosin structure organization
GO:0031589 cell-substrate adhesion
GO:0046777 protein autophosphorylation
GO:0051259 protein oligomerization
GO:0051262 protein tetramerization
GO:0070265 necrotic cell death
GO:0070266 necroptotic process
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097300 programmed necrotic cell death
Molecular Function GO:0003779 actin binding
GO:0004674 protein serine/threonine kinase activity
GO:0005216 ion channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0017022 myosin binding
GO:0022803 passive transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0001726 ruffle
GO:0031252 cell leading edge
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
hsa04978 Mineral absorption
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-3295583: TRP channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRPM7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRPM7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRPM7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4240.193
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8310.531
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1250.903
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0340.896
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2720.909
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2650.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0840.823
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.330.857
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1890.926
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3140.777
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1640.454
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0750.137
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRPM7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRPM7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRPM7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRPM7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRPM7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRPM7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRPM7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRPM7
Nametransient receptor potential cation channel, subfamily M, member 7
Aliases CHAK1; LTRPC7; TRP-PLIK; ALSPDC; CHAK; LTrpC-7; LTRPC ion channel family member 7; channel-kinase 1; long tr ......
Chromosomal Location15q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRPM7 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TRPM7.
ID Name Drug Type Targets #Targets
DB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall MoleculeACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......26
DB044471,4-DithiothreitolSmall MoleculeALDH1A1, AXIN1, CAMK2A, GSTZ1, HMGCR, LGALS1, MSRA, PPIB, TPI1, TR ......10